Tryp Therapeutics Inc.

Recent News

  • Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference

    San Diego, California--(Newsfile Corp. - August 3, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the Canaccord Genuity Virtual Growth Conference.The conference will be held virtually on August 10-12, 2021. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN™) program for...

    2021-08-03 7:05 AM EDT
  • Tryp Therapeutics Announces Q3 2021 Financial Results

    San Diego, California--(Newsfile Corp. - July 28, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today its interim financial results for the three and nine month period ended May 31, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system...

    2021-07-28 11:19 PM EDT
  • Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D. as Scientific Advisor

    San Diego, California--(Newsfile Corp. - July 26, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today the appointment of Robin Carhart-Harris, Ph.D. as Chairman of its Scientific Advisory Board ("SAB") and Daniel Clauw, M.D. as a new member of the SAB.Dr. Carhart-Harris initially joined Tryp's SAB in February 2021 and has since been instrumental in advising the Company through the...

    2021-07-26 9:43 AM EDT
  • Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

    San Diego, California--(Newsfile Corp. - July 21, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today its plans to conduct a Phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School.The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of...

    2021-07-21 7:00 AM EDT
  • Tryp Therapeutics to Host Q3 Investor Day on July 29, 2021

    San Diego, California--(Newsfile Corp. - July 15, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will host their Q3 Investor Day on July 29, 2021 at 9:00 a.m. PDT.The event will include a presentation by Tryp's management team to discuss updates on its Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program as well as upcoming milestones for 2021 and beyond. The...

    2021-07-15 7:00 AM EDT
  • Tryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary Formulations

    San Diego, California--(Newsfile Corp. - July 7, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB:TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with the University of Michigan to perform research related to Tryp's Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program.Tryp's collaboration with the University of Michigan is part of a series of upcoming bridging studies designed to expand Tryp's intellectual property portfolio for the company's novel TRP-8803...

    2021-07-07 7:00 AM EDT
  • Tryp Therapeutics to Present at the Psych Investor Summit

    San Diego, California--(Newsfile Corp. - June 24, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the Psych Investor Summit: Research & Development. The conference will be held virtually on July 7. Greg McKee, Chairman and CEO, will present information on the company and its drug development pipeline in addition to...

    2021-06-24 7:00 AM EDT
  • Tryp Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

    San Diego, California--(Newsfile Corp. - June 8, 2021) -  Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually on July 13 and 14. Greg McKee, Chairman and CEO; Jim Gilligan, President and Chief Science Officer; and Luke Hayes, CFO, will provide an overview of Tryp's...

    2021-06-08 7:00 AM EDT